Galmed Pharmaceuticals (GLMD) EBIT (QoQ) (2013 - 2023)
Galmed Pharmaceuticals (GLMD) EBIT (QoQ) (2013 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.32 Mn | -9.56 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 197.45% |
| Sep 30, 2022 | -111.89% |
| Mar 31, 2021 | 100.08% |
| Dec 31, 2020 | -199.86% |
| Sep 30, 2020 | 7,126.29% |
| Jun 30, 2020 | -190.00% |
| Mar 31, 2020 | -92.30% |
| Dec 31, 2019 | 17,594.51% |
| Sep 30, 2019 | 110.08% |
| Jun 30, 2019 | -216.36% |
| Mar 31, 2019 | -0.44% |
| Dec 31, 2018 | 231.00% |
| Sep 30, 2018 | 938.98% |
| Jun 30, 2018 | -95.39% |
| Mar 31, 2018 | -30.41% |
| Dec 31, 2017 | 29.75% |
| Sep 30, 2017 | 3.43% |
| Jun 30, 2017 | -16.05% |
| Mar 31, 2017 | -33.24% |
| Dec 31, 2016 | 28.49% |